Evidence map›Paper›PMID 26190462›Full record

ArticleBioorganic & medicinal chemistry2015

Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

Mandi M Murph, Guowei W Jiang, Molly K Altman, Wei Jia, Duy T Nguyen, Jada M Fambrough, William J Hardman, Ha T Nguyen, Sterling K Tran, Ali A Alshamrani and 3 more

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Silver-Catalyzed (Journal of the American Chemical Society · 2024
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mandi M MurphDepartment of Pharmaceutical and Biomedical Sciences, The University of Georgia, College of Pharmacy, 240 W. Green Street, Athens, GA 30602, United States. Electronic address: mmurph@uga.edu.
Guowei W JiangDepartment of Medicinal Chemistry, The University of Utah, 419 Wakara Way, Suite 205, Salt Lake City, UT 84108-1257, United States.
Molly K AltmanDepartment of Pharmaceutical and Biomedical Sciences, The University of Georgia, College of Pharmacy, 240 W. Green Street, Athens, GA 30602, United States.
Wei JiaDepartment of Pharmaceutical and Biomedical Sciences, The University of Georgia, College of Pharmacy, 240 W. Green Street, Athens, GA 30602, United States.
Duy T NguyenDepartment of Pharmaceutical and Biomedical Sciences, The University of Georgia, College of Pharmacy, 240 W. Green Street, Athens, GA 30602, United States.
Jada M FambroughDepartment of Pharmaceutical and Biomedical Sciences, The University of Georgia, College of Pharmacy, 240 W. Green Street, Athens, GA 30602, United States.
William J HardmanThe University of Georgia and Georgia Regents University Medical Partnership, 1425 Prince Avenue, Athens, GA 30606, United States.
Ha T NguyenDepartment of Pharmaceutical and Biomedical Sciences, The University of Georgia, College of Pharmacy, 240 W. Green Street, Athens, GA 30602, United States.
Sterling K TranDepartment of Pharmaceutical and Biomedical Sciences, The University of Georgia, College of Pharmacy, 240 W. Green Street, Athens, GA 30602, United States.
Ali A AlshamraniDepartment of Pharmaceutical and Biomedical Sciences, The University of Georgia, College of Pharmacy, 240 W. Green Street, Athens, GA 30602, United States.
Damian MadanEchelon Biosciences Incorporated, 675 Arapeen Way, Suite 302, Salt Lake City, UT 84108, United States.
Jianxing ZhangDepartment of Medicinal Chemistry, The University of Utah, 419 Wakara Way, Suite 205, Salt Lake City, UT 84108-1257, United States.
Glenn D PrestwichDepartment of Medicinal Chemistry, The University of Utah, 419 Wakara Way, Suite 205, Salt Lake City, UT 84108-1257, United States. Electronic address: gprestwich@pharm.utah.edu.

Funding

Phosphoinositide and Inositol Polyphosphate ProbesR01NS029632 · NINDS · UNIVERSITY OF UTAH · PI PRESTWICH, GLENN DOWNES · 1992 to 2007
$2.5M
Endotoxin Generated Lipid Second MessengersR01HL070231 · NHLBI · UNIVERSITY OF UTAH · PI MCINTYRE, THOMAS M · 2003 to 2006
$1.3M
NHLBI NIH HHS HL 070231NHLBI NIH HHS R01 HL070231NINDS NIH HHS NS 29632NINDS NIH HHS R01 NS029632
6 · The paper itself

Abstract

Autotaxin (ATX) is an enzyme discovered in the conditioned medium of cultured melanoma cells and identified as a protein that strongly stimulates motility. This unique ectonucleotide pyrophosphatase and phosphodiesterase facilitates the removal of a choline headgroup from lysophosphatidylcholine (LPC) to yield lysophosphatidic acid (LPA), which is a potent lipid stimulator of tumorigenesis. Thus, ATX has received renewed attention because it has a prominent role in malignant progression with significant translational potential. Specifically, we sought to develop active site-targeted irreversible inhibitors as anti-cancer agents. Herein we describe the synthesis and biological activity of an LPC-mimetic electrophilic affinity label that targets the active site of ATX, which has a critical threonine residue that acts as a nucleophile in the lysophospholipase D reaction to liberate choline. We synthesized a set of quaternary ammonium derivative-containing vinyl sulfone analogs of LPC that function as irreversible inhibitors of ATX and inactivate the enzyme. The analogs were tested in cell viability assays using multiple cancer cell lines. The IC50 values ranged from 6.74 to 0.39 μM, consistent with a Ki of 3.50 μM for inhibition of ATX by the C16H33 vinyl sulfone analog CVS-16 (10b). A phenyl vinyl sulfone control compound, PVS-16, lacking the choline-like quaternary ammonium mimicking head group moiety, had little effect on cell viability and did not inhibit ATX. Most importantly, CVS-16 (10b) significantly inhibited melanoma progression in an in vivo tumor model by preventing angiogenesis. Taken together, this suggests that CVS-16 (10b) is a potent and irreversible ATX inhibitor with significant biological activity both in vitro and in vivo.

Indexed as

Cell Line, TumorHumansLysophosphatidylcholinesMelanomaNeovascularization, PathologicSulfonesLysophosphatidylcholinesphenyl vinyl sulfoneSulfonesAngiogenesisAnticancer therapyAutotaxinLysophosphatidylcholineMelanomaVinyl sulfone

Identifiers

PMID26190462
PMCPMC4554797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.